Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NATR's Cash to Debt is ranked higher than
98% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. NATR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NATR' s Cash to Debt Range Over the Past 10 Years
Min: 2.51  Med: 21.55 Max: No Debt
Current: No Debt
Equity to Asset 0.64
NATR's Equity to Asset is ranked higher than
52% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NATR: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
NATR' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.63 Max: 0.73
Current: 0.64
0.31
0.73
Interest Coverage No Debt
NATR's Interest Coverage is ranked higher than
97% of the 468 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.86 vs. NATR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NATR' s Interest Coverage Range Over the Past 10 Years
Min: 13.14  Med: 105.43 Max: 9999.99
Current: No Debt
13.14
9999.99
F-Score: 6
Z-Score: 3.61
M-Score: -2.47
WACC vs ROIC
7.75%
10.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 3.30
NATR's Operating margin (%) is ranked lower than
64% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. NATR: 3.30 )
Ranked among companies with meaningful Operating margin (%) only.
NATR' s Operating margin (%) Range Over the Past 10 Years
Min: 0.83  Med: 3.75 Max: 9.26
Current: 3.3
0.83
9.26
Net-margin (%) 3.43
NATR's Net-margin (%) is ranked lower than
61% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.02 vs. NATR: 3.43 )
Ranked among companies with meaningful Net-margin (%) only.
NATR' s Net-margin (%) Range Over the Past 10 Years
Min: -2.25  Med: 2.26 Max: 6.91
Current: 3.43
-2.25
6.91
ROE (%) 8.41
NATR's ROE (%) is ranked higher than
56% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.02 vs. NATR: 8.41 )
Ranked among companies with meaningful ROE (%) only.
NATR' s ROE (%) Range Over the Past 10 Years
Min: -12.81  Med: 9.87 Max: 25
Current: 8.41
-12.81
25
ROA (%) 5.52
NATR's ROA (%) is ranked higher than
61% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. NATR: 5.52 )
Ranked among companies with meaningful ROA (%) only.
NATR' s ROA (%) Range Over the Past 10 Years
Min: -5.25  Med: 4.44 Max: 13.73
Current: 5.52
-5.25
13.73
ROC (Joel Greenblatt) (%) 14.22
NATR's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.79 vs. NATR: 14.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NATR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 15.41  Med: 46.28 Max: 120.79
Current: 14.22
15.41
120.79
Revenue Growth (3Y)(%) -9.70
NATR's Revenue Growth (3Y)(%) is ranked lower than
82% of the 605 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NATR: -9.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NATR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.7  Med: 3.50 Max: 8.7
Current: -9.7
-9.7
8.7
EBITDA Growth (3Y)(%) -27.80
NATR's EBITDA Growth (3Y)(%) is ranked lower than
90% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. NATR: -27.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NATR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.8  Med: 0.20 Max: 29.8
Current: -27.8
-27.8
29.8
EPS Growth (3Y)(%) -25.40
NATR's EPS Growth (3Y)(%) is ranked lower than
85% of the 509 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. NATR: -25.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NATR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.3  Med: -1.30 Max: 59.2
Current: -25.4
-29.3
59.2
» NATR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

NATR Guru Trades in Q2 2015

Jim Simons 245,500 sh (+17.07%)
Chuck Royce Sold Out
» More
Q3 2015

NATR Guru Trades in Q3 2015

Jim Simons 269,700 sh (+9.86%)
» More
Q4 2015

NATR Guru Trades in Q4 2015

Jim Simons 287,100 sh (+6.45%)
» More
Q1 2016

NATR Guru Trades in Q1 2016

Jim Simons 340,100 sh (+18.46%)
» More
» Details

Insider Trades

Latest Guru Trades with NATR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:SNDX, OTCPK:ORXOY, NAS:BPTH, OTCPK:ARSUF, NAS:DRRX, NAS:ARLZ, NAS:RIGL, OTCPK:TWMJF, OTCPK:DGTLF, NAS:AGRX, NAS:NEOS, OTCPK:SENZ, NAS:TTPH, OTCPK:ELTP, NAS:CPHR, OTCPK:SCLRF, NAS:LPCN, NAS:MSLI, OTCPK:TBUFF, NAS:AQXP » details
Natures Sunshine Products Inc is a natural health and wellness company. The Company, together with its subsidiaries is engaged in the manufacturing and direct selling of nutritional and personal care products.

Natures Sunshine Products Inc, was founded in 1972 and incorporated in Utah in 1976. The Company together with its subsidiaries is a natural health and wellness company engaged in the manufacturing and direct selling of nutritional and personal care products. The Company sells its products to a sales force of independent Managers and Distributors who use the products themselves or resell them to other distributors or customers. The Company has four business segments that are divided based on the different characteristics of their Distributor bases, selling and Distributor compensation plans and product formulations, as well as the internal organization of its officers and their responsibilities and business operations. Three business segments operate under the Nature's Sunshine Products brand (NSP Americas; NSP Russia, Central and Eastern Europe; and China and New Markets). The Company's China and New Markets segment is deploying a multi-channel go-to-market strategy that offers select Nature's Sunshine branded products through a direct selling model across China as well as through e-commerce channels. The time to market will be dependent upon regulatory processes including product registration and permit approvals. Due to a change in the Chinese regulatory environment, the Company has indefinitely deferred its entry into the retail channel in China. The China and New Markets segment also includes the Company's wholesale business, in which the Company sells its products to various locally managed entities independent of the Company that have distribution rights for the relevant market. All of the net sales revenue to date in the China and New Markets segment is through the Company's wholesale business to foreign markets outside of China detailed below. The wholesale business was previously part of NSP Americas. The fourth business segment operates under the Synergy Worldwide brand. The Company markets its products in Australia, Austria, Belarus, Canada, Colombia, Costa Rica, the Czech Republic, Denmark, the Dominican Republic, Ecuador, El Salvador, Finland, Germany, Guatemala, Honduras, Hong Kong, Iceland, Indonesia, Ireland, Italy, Japan, Kazakhstan, Latvia, Lithuania, Malaysia, Mexico, Moldova, Mongolia, the Netherlands, New Zealand, Nicaragua, Norway, Panama, the Philippines, Poland, Russia, Singapore, Slovenia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, the United Kingdom, and the United States. The Company markets its products through a wholesale model to Argentina, Australia, Chile, Israel, New Zealand, Norway, Peru and the United Kingdom. The Company's products are also regulated by the Federal Trade Commission, the Consumer Product Safety Commission, the United States Department of Agriculture and the Environmental Protection Agency.

Ratios

vs
industry
vs
history
P/E(ttm) 17.05
NATR's P/E(ttm) is ranked higher than
70% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.34 vs. NATR: 17.05 )
Ranked among companies with meaningful P/E(ttm) only.
NATR' s P/E(ttm) Range Over the Past 10 Years
Min: 7.88  Med: 17.55 Max: 159.88
Current: 17.05
7.88
159.88
PE(NRI) 19.80
NATR's PE(NRI) is ranked higher than
65% of the 533 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.24 vs. NATR: 19.80 )
Ranked among companies with meaningful PE(NRI) only.
NATR' s PE(NRI) Range Over the Past 10 Years
Min: 7.89  Med: 15.09 Max: 87
Current: 19.8
7.89
87
P/B 1.38
NATR's P/B is ranked higher than
75% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. NATR: 1.38 )
Ranked among companies with meaningful P/B only.
NATR' s P/B Range Over the Past 10 Years
Min: 1.04  Med: 2.12 Max: 3.88
Current: 1.38
1.04
3.88
P/S 0.61
NATR's P/S is ranked higher than
88% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. NATR: 0.61 )
Ranked among companies with meaningful P/S only.
NATR' s P/S Range Over the Past 10 Years
Min: 0.21  Med: 0.62 Max: 1.95
Current: 0.61
0.21
1.95
POCF 13.60
NATR's POCF is ranked higher than
61% of the 254 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.49 vs. NATR: 13.60 )
Ranked among companies with meaningful POCF only.
NATR' s POCF Range Over the Past 10 Years
Min: 6.32  Med: 12.73 Max: 162.25
Current: 13.6
6.32
162.25
EV-to-EBIT 13.68
NATR's EV-to-EBIT is ranked higher than
68% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.96 vs. NATR: 13.68 )
Ranked among companies with meaningful EV-to-EBIT only.
NATR' s EV-to-EBIT Range Over the Past 10 Years
Min: 3.1  Med: 9.10 Max: 136.6
Current: 13.68
3.1
136.6
EV-to-EBITDA 9.36
NATR's EV-to-EBITDA is ranked higher than
74% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.28 vs. NATR: 9.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
NATR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.5  Med: 7.10 Max: 31.5
Current: 9.36
2.5
31.5
Shiller P/E 22.04
NATR's Shiller P/E is ranked higher than
77% of the 149 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.12 vs. NATR: 22.04 )
Ranked among companies with meaningful Shiller P/E only.
NATR' s Shiller P/E Range Over the Past 10 Years
Min: 7.62  Med: 21.29 Max: 47.62
Current: 22.04
7.62
47.62
Current Ratio 1.77
NATR's Current Ratio is ranked lower than
64% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. NATR: 1.77 )
Ranked among companies with meaningful Current Ratio only.
NATR' s Current Ratio Range Over the Past 10 Years
Min: 1.32  Med: 2.08 Max: 2.48
Current: 1.77
1.32
2.48
Quick Ratio 1.10
NATR's Quick Ratio is ranked lower than
72% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. NATR: 1.10 )
Ranked among companies with meaningful Quick Ratio only.
NATR' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.30 Max: 1.79
Current: 1.1
0.83
1.79
Days Inventory 172.42
NATR's Days Inventory is ranked lower than
75% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.06 vs. NATR: 172.42 )
Ranked among companies with meaningful Days Inventory only.
NATR' s Days Inventory Range Over the Past 10 Years
Min: 163.98  Med: 189.94 Max: 212.68
Current: 172.42
163.98
212.68
Days Sales Outstanding 9.20
NATR's Days Sales Outstanding is ranked higher than
94% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.75 vs. NATR: 9.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
NATR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.2  Med: 8.75 Max: 10.32
Current: 9.2
6.2
10.32
Days Payable 36.97
NATR's Days Payable is ranked lower than
80% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.79 vs. NATR: 36.97 )
Ranked among companies with meaningful Days Payable only.
NATR' s Days Payable Range Over the Past 10 Years
Min: 20.87  Med: 26.40 Max: 44.57
Current: 36.97
20.87
44.57

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.04
NATR's Dividend Yield is ranked higher than
86% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. NATR: 4.04 )
Ranked among companies with meaningful Dividend Yield only.
NATR' s Dividend Yield Range Over the Past 10 Years
Min: 0.3  Med: 2.37 Max: 5.34
Current: 4.04
0.3
5.34
Dividend Payout 0.75
NATR's Dividend Payout is ranked lower than
83% of the 376 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.33 vs. NATR: 0.75 )
Ranked among companies with meaningful Dividend Payout only.
NATR' s Dividend Payout Range Over the Past 10 Years
Min: 0.1  Med: 0.16 Max: 1.67
Current: 0.75
0.1
1.67
Dividend Growth (3y) 38.70
NATR's Dividend Growth (3y) is ranked higher than
92% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. NATR: 38.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NATR' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 44.2
Current: 38.7
0
44.2
Forward Dividend Yield 4.04
NATR's Forward Dividend Yield is ranked higher than
85% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. NATR: 4.04 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.05
NATR's Yield on cost (5-Year) is ranked higher than
75% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.01 vs. NATR: 4.05 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NATR' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.3  Med: 2.37 Max: 5.34
Current: 4.05
0.3
5.34
3-Year Average Share Buyback Ratio -5.50
NATR's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 424 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. NATR: -5.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NATR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.2  Med: -0.10 Max: 4.8
Current: -5.5
-6.2
4.8

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 5.47
NATR's Price/Net Current Asset Value is ranked higher than
58% of the 438 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.67 vs. NATR: 5.47 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NATR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.84  Med: 5.57 Max: 118.75
Current: 5.47
2.84
118.75
Price/Tangible Book 1.38
NATR's Price/Tangible Book is ranked higher than
78% of the 688 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. NATR: 1.38 )
Ranked among companies with meaningful Price/Tangible Book only.
NATR' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.34  Med: 2.27 Max: 10.63
Current: 1.38
1.34
10.63
Price/Projected FCF 1.22
NATR's Price/Projected FCF is ranked higher than
77% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. NATR: 1.22 )
Ranked among companies with meaningful Price/Projected FCF only.
NATR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.42  Med: 1.24 Max: 2.37
Current: 1.22
0.42
2.37
Price/Median PS Value 0.95
NATR's Price/Median PS Value is ranked higher than
60% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. NATR: 0.95 )
Ranked among companies with meaningful Price/Median PS Value only.
NATR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.34  Med: 1.05 Max: 3.66
Current: 0.95
0.34
3.66
Price/Graham Number 1.10
NATR's Price/Graham Number is ranked higher than
78% of the 409 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. NATR: 1.10 )
Ranked among companies with meaningful Price/Graham Number only.
NATR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.66  Med: 1.29 Max: 4.2
Current: 1.1
0.66
4.2
Earnings Yield (Greenblatt) (%) 7.33
NATR's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. NATR: 7.33 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NATR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 11.00 Max: 32.8
Current: 7.33
0.7
32.8
Forward Rate of Return (Yacktman) (%) -10.98
NATR's Forward Rate of Return (Yacktman) (%) is ranked lower than
82% of the 326 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.89 vs. NATR: -10.98 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NATR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -15.8  Med: 4.10 Max: 39.9
Current: -10.98
-15.8
39.9

More Statistics

Revenue (TTM) (Mil) $323.2
EPS (TTM) $ 0.58
Beta0.80
Short Percentage of Float2.69%
52-Week Range $7.15 - 14.11
Shares Outstanding (Mil)18.72
» More Articles for NATR

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight Jun 05 2016 
Nature's Sunshine CEO Resigns and Director Buys 365,000 Shares Mar 12 2013 
Is Nature’s Sunshine Breaking Through the Clouds? Mar 28 2012 

More From Other Websites
NSP Named One of America's Healthiest Companies for Nine Consecutive Years Jun 23 2016
Nature’s Sunshine Products Named One of America’s Healthiest Companies for Nine Consecutive... Jun 23 2016
ETF’s with exposure to Nature’s Sunshine Products, Inc. : June 20, 2016 Jun 20 2016
NATURES SUNSHINE PRODUCTS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 03 2016
NATURES SUNSHINE PRODUCTS INC Financials May 19 2016
Nature’s Sunshine Products to Present at the 17th Annual B. Riley & Co. Investor Conference May 18 2016
Nature’s Sunshine Products, Inc. :NATR-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
NATURES SUNSHINE PRODUCTS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 11 2016
Nature's Sunshine posts 1Q profit May 10 2016
Nature's Sunshine posts 1Q profit May 10 2016
Nature’s Sunshine Products Reports First Quarter 2016 Financial Results May 10 2016
NATURES SUNSHINE PRODUCTS INC Files SEC form 10-Q, Quarterly Report May 10 2016
Nature's Sunshine Products Reports First Quarter 2016 Financial Results May 10 2016
Q1 2016 Natures Sunshine Products Inc Earnings Release - 4:00 pm ET May 10 2016
Prescott Group is Betting Big on These Micro-Cap Stocks for Q2 May 02 2016
Nature’s Sunshine to Announce First Quarter 2016 Financial Results and to Host Conference Call on... Apr 26 2016
Nature’s Sunshine Products to Announce First Quarter 2016 Financial Results and to Host Conference... Apr 26 2016
Nature’s Sunshine Honored as a Top Global Company by Direct Selling News Apr 25 2016
Nature’s Sunshine Honored as a Top Global Company by Direct Selling News Apr 25 2016
Nature’s Sunshine Launches Patent-Pending Program to Reverse Cardiometabolic Dysfunction Apr 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)